Advancements in the treatment of keratinocyte carcinoma have broadened therapeutic opportunities for patients who elect to avoid surgery or are poor surgical candidates. Due to this evolving landscape of pharmacologic (topical, intralesional or systemic), photodynamic, laser and radiation based, and minimally-invasive treatments (either field-directed, lesion-directed, and/or systemic), providers may be faced with uncertainty in selecting an optimal alternative to surgical care. Part 2 of this CME will outline established and emerging evidence-based treatment and preventive therapies for keratinocyte carcinoma to guide care for patients with surgical contraindications.